血清CA125、CEA、HE4水平对卵巢癌患者临床转归的预测价值  

The Predictive Value of Serum CA125,CEA,and HE4 Levels for Clinical Outcomes in Ovarian Cancer Patients

作　　者：常捷芳 李娟 CHANG Jiefang;LI Juan(Department of Gynecology,Hanzhong Central Hospital,Hanzhong Shaanxi 723000)

机构地区：[1]汉中市中心医院妇科,陕西汉中723000 [2]咸阳市妇幼保健院检验科,陕西咸阳712000

出　　处：《医学临床研究》2023年第9期1292-1295,共4页Journal of Clinical Research

摘　　要：【目的】探讨血清糖类抗原125(CA125)、癌胚抗原(CEA)、人附睾蛋白4(HE4)水平对卵巢癌患者临床转归的预测价值。【方法】选取2020年5月至2022年7月汉中市中心医院收治的159例卵巢癌患者(卵巢癌组),另选取同期在汉中市中心医院体检的138例健康志愿者(健康组)为对照。比较两组血清CA125、CEA、HE4水平,卵巢癌组化疗3个疗程后,统计患者临床转归情况,比较好转组和不良转归组患者临床资料,分析临床转归的影响因素及血清CA125、CEA、HE4水平对卵巢癌患者临床好转的预测价值。【结果】卵巢癌组血清CA125、CEA、HE4水平均高于健康组(P<0.05);好转组患者血清CA125、CEA、HE4水平均低于不良转归组(P<0.05);好转组患者难治性腹水、淋巴结转移构成比与不良转归组患者比较,差异均有统计学意义(P<0.05);血清CA125、CEA、HE4水平及难治性腹水均是影响临床转归的相关因素(P<0.05);受试者工作特征(ROC)曲线分析结果显示:血清CA125、CEA、HE4水平预测卵巢癌患者临床好转的最佳截断点分别为541.39 U/mL、4.96 ng/mL、230.79 pmol/L,特异度分别为71.21%、75.76%、77.27%,曲线下面积(AUC)分别为0.750、0.709、0.782,三者联合预测的特异度和AUC分别为96.97%、0.820。【结论】卵巢癌临床好转患者血清CA125、CEA、HE4水平均低于不良转归患者,血清CA125、CEA、HE4水平均是影响卵巢癌患者临床转归的相关因素,血清CA125、CEA、HE4水平均可作为预测卵巢癌临床转归的敏感指标,且联合预测价值更高。【Objective】To explore the predictive value of serum levels of carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and human epididymal protein 4(HE4)in the clinical prognosis of ovarian cancer patients.【Methods】A total of 159 ovarian cancer patients(ovarian cancer group)admitted to the Hanzhong Central Hospital from May 2020 to July 2022 were selected,and 138 healthy volunteers(health group)who underwent physical examinations at Hanzhong Central Hospital during the same period were selected as controls.Compare the serum levels of CA125,CEA,and HE4 between the two groups,and analyze the clinical outcomes of the ovarian cancer group after three courses of chemotherapy.We compared the clinical data of patients in the improvement group and the adverse outcome group,analyzed the influencing factors of clinical outcome,and the predictive value of serum CA125,CEA,and HE4 levels for clinical improvement in ovarian cancer patients.【Results】The serum levels of CA125,CEA,and HE4 in the ovarian cancer group were higher than those in the healthy group(P<0.05);The serum levels of CA125,CEA,and HE4 in the improvement group were lower than those in the adverse outcome group(P<0.05);The difference in the proportion of refractory ascites and lymph node metastasis between the improvement group and the adverse outcome group was statistically significant(P<0.05);Serum levels of CA125,CEA,HE4,and refractory ascites are all related factors that affect clinical improvement(P<0.05);The analysis results of the receiver operating characteristic(ROC)curve showed that the optimal cutoff points for predicting clinical improvement in ovarian cancer patients with serum CA125,CEA,and HE4 levels were 541.39 U/mL,4.96 ng/mL,and 230.79 pmol/L,respectively,with specificity of 71.21%,75.76%,and 77.27%.The area under the curve(AUC)was 0.750,0.709,and 0.782,respectively.The specificity and AUC predicted by the combination of the three were 96.97%and 0.820,respectively.【Conclusion】Serum levels of CA125,CEA,and HE4 in patients w

关 键 词：卵巢肿瘤 癌胚抗原/血液 CA-125抗原/血液 附睾分泌蛋白质类/血液 

分 类 号：R737.31[医药卫生—肿瘤]